Kimberly-Clark (KMB) shares plunged over 15% premarket on Monday after the consumer goods firm entered a deal to acquire all outstanding shares of Tylenol-maker Kenvue (KVUE) in a cash and stock transaction. The transaction is expected to close in the second half of 2026, subject to the receipt of shareholder approvals and regulatory approvals. The deal values Kenvue (KVUE) at an enterprise value of around $48.7 billion, based on the closing price of Kimberly-Clark common stock on October 31, 2025. Under the agreement, unanimously approved by both boards, Kenvue shareholders will receive $3.50 in cash and 0.14625 shares of Kimberly-Clark...